Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated a Neutral rating on Bristol-Myers Squibb (NYSE:BMY) and maintained a $45 price target.
July 22, 2024 | 3:24 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated a Neutral rating on Bristol-Myers Squibb (NYSE:BMY) and maintained a $45 price target. This suggests that the analyst does not foresee significant short-term movement in the stock price.
The reiteration of a Neutral rating and the maintenance of the price target at $45 indicate that the analyst does not expect significant short-term changes in the stock price. This suggests a stable outlook for the company in the near term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100